Universal Beteiligungs und Servicegesellschaft mbH Reduces Stock Holdings in Ralliant Corporation $RAL

Universal Beteiligungs und Servicegesellschaft mbH cut its stake in shares of Ralliant Corporation (NYSE:RAL) by 49.8% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 94,530 shares of the company’s stock after selling 93,960 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Ralliant were worth $4,134,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of RAL. ORG Partners LLC purchased a new stake in shares of Ralliant during the second quarter worth about $70,000. Nordea Investment Management AB purchased a new position in Ralliant in the second quarter valued at about $29,477,000. Cullen Frost Bankers Inc. acquired a new stake in Ralliant during the 2nd quarter valued at approximately $144,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new stake in Ralliant during the 2nd quarter worth approximately $1,410,000. Finally, Boston Partners purchased a new stake in Ralliant during the 2nd quarter worth approximately $63,656,000.

Analyst Upgrades and Downgrades

Several research firms have recently commented on RAL. Weiss Ratings reiterated a “hold (c)” rating on shares of Ralliant in a research note on Monday, December 29th. Royal Bank Of Canada increased their price objective on shares of Ralliant from $45.00 to $52.00 and gave the company a “sector perform” rating in a research note on Friday, November 7th. Oppenheimer raised their price objective on shares of Ralliant from $55.00 to $60.00 and gave the stock an “outperform” rating in a report on Monday, December 15th. Barclays upped their target price on shares of Ralliant from $59.00 to $60.00 and gave the company an “overweight” rating in a research note on Wednesday, January 7th. Finally, Citigroup raised Ralliant from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $53.00 to $61.00 in a report on Monday, December 8th. Six research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, Ralliant currently has an average rating of “Moderate Buy” and a consensus target price of $58.00.

Ralliant Stock Performance

Shares of RAL stock opened at $53.42 on Wednesday. The company has a market cap of $6.03 billion and a P/E ratio of 42.06. The business has a 50 day moving average of $51.06 and a two-hundred day moving average of $46.55. Ralliant Corporation has a 52 week low of $40.70 and a 52 week high of $55.25. The company has a quick ratio of 1.03, a current ratio of 1.49 and a debt-to-equity ratio of 0.39.

Ralliant (NYSE:RAL) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.02. The company had revenue of $529.10 million during the quarter, compared to the consensus estimate of $519.14 million. Ralliant has set its Q4 2025 guidance at 0.620-0.680 EPS.

Ralliant Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 23rd. Stockholders of record on Monday, December 8th were issued a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, December 8th. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. Ralliant’s payout ratio is 15.75%.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.